Association between sensitivity of viral thymidine kinase-associated acyclovir-resistant herpes simplex virus type 1 and virulence. 2017

Natsumi Omura, and Hikaru Fujii, and Tomoki Yoshikawa, and Souichi Yamada, and Shizuko Harada, and Takuya Inagaki, and Miho Shibamura, and Haruko Takeyama, and Masayuki Saijo
Department of Virology 1, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan.

Acyclovir (ACV)-resistant (ACVr) herpes simplex virus type 1 (HSV-1) infections are concern in immunocompromised patients. Most clinical ACVr HSV-1 isolates have mutations in the viral thymidine kinase (vTK) genes. The vTK-associated ACVr HSV-1 shows reduced virulence, but the association between the level of resistance and the virulence of the vTK-associated ACVr HSV-1 is still unclear. The virulence in mice of 5 vTK-associated ACVr HSV-1 clones with a variety of ACV sensitivities, when inoculated through intracerebral and corneal routes, was evaluated in comparison with ACV-sensitive (ACVs) parent HSV-1 TAS. Although all the 5 ACVr HSV-1 clones and ACVs HSV-1 TAS showed a similar single-step growth capacity in vitro, the virulence of ACVr HSV-1 clones significantly decreased. A 50% lethal dose (LD50) of each clone was closely correlated with 50% inhibitory concentrations (IC50), demonstrating that the higher the ACV-sensitvity, the the higher the virulence among the ACVr clones. One of the ACVr HSV-1 clones with a relatively low IC50 value maintained similar virulence to that of the parent TAS. The infection in mice with ACVr HSV-1 due to a single amino acid substitution in vTK induced local diseases, keratitis and dermatitis, while vTK-deficient clone did not. A statistically significant correlation between the virulence and susceptibility to ACV among ACVr HSV-1 clones was demonstrated.

UI MeSH Term Description Entries
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005260 Female Females
D006561 Herpes Simplex A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.) Herpes Simplex Virus Infection
D000212 Acyclovir A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes. Acycloguanosine,9-((2-Hydroxyethoxy)methyl)guanine,Aci-Sanorania,Acic,Aciclobeta,Aciclostad,Aciclovir,Aciclovir Alonga,Aciclovir-Sanorania,Acifur,Acipen Solutab,Acivir,Activir,Acyclo-V,Acyclovir Sodium,Antiherpes Creme,Avirax,Cicloferon,Clonorax,Cusiviral,Genvir,Herpetad,Herpofug,Herpotern,Herpoviric,Isavir,Laciken,Mapox,Maynar,Milavir,Opthavir,Supraviran,Viclovir,Vipral,Virax-Puren,Virherpes,Virmen,Virolex,Virupos,Virzin,Wellcome-248U,Zoliparin,Zovirax,Zyclir,aciclovir von ct,Aci Sanorania,Aciclovir Sanorania,Acyclo V,Alonga, Aciclovir,Sodium, Acyclovir,Solutab, Acipen,Virax Puren,ViraxPuren,Wellcome 248U,Wellcome248U
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D013937 Thymidine Kinase An enzyme that catalyzes the conversion of ATP and thymidine to ADP and thymidine 5'-phosphate. Deoxyuridine can also act as an acceptor and dGTP as a donor. (From Enzyme Nomenclature, 1992) EC 2.7.1.21. Deoxythymidine Kinase,Deoxypyrimidine Kinase,Kinase, Deoxypyrimidine,Kinase, Deoxythymidine,Kinase, Thymidine
D014774 Virulence The degree of pathogenicity within a group or species of microorganisms or viruses as indicated by case fatality rates and/or the ability of the organism to invade the tissues of the host. The pathogenic capacity of an organism is determined by its VIRULENCE FACTORS. Pathogenicity
D050505 Mutant Proteins Proteins produced from GENES that have acquired MUTATIONS. Mutant Protein,Protein, Mutant,Proteins, Mutant

Related Publications

Natsumi Omura, and Hikaru Fujii, and Tomoki Yoshikawa, and Souichi Yamada, and Shizuko Harada, and Takuya Inagaki, and Miho Shibamura, and Haruko Takeyama, and Masayuki Saijo
May 1982, Journal of virology,
Natsumi Omura, and Hikaru Fujii, and Tomoki Yoshikawa, and Souichi Yamada, and Shizuko Harada, and Takuya Inagaki, and Miho Shibamura, and Haruko Takeyama, and Masayuki Saijo
February 2007, Antiviral research,
Natsumi Omura, and Hikaru Fujii, and Tomoki Yoshikawa, and Souichi Yamada, and Shizuko Harada, and Takuya Inagaki, and Miho Shibamura, and Haruko Takeyama, and Masayuki Saijo
March 2002, Journal of medical virology,
Natsumi Omura, and Hikaru Fujii, and Tomoki Yoshikawa, and Souichi Yamada, and Shizuko Harada, and Takuya Inagaki, and Miho Shibamura, and Haruko Takeyama, and Masayuki Saijo
October 1992, Journal of medicinal chemistry,
Natsumi Omura, and Hikaru Fujii, and Tomoki Yoshikawa, and Souichi Yamada, and Shizuko Harada, and Takuya Inagaki, and Miho Shibamura, and Haruko Takeyama, and Masayuki Saijo
September 1996, The Journal of infectious diseases,
Natsumi Omura, and Hikaru Fujii, and Tomoki Yoshikawa, and Souichi Yamada, and Shizuko Harada, and Takuya Inagaki, and Miho Shibamura, and Haruko Takeyama, and Masayuki Saijo
August 1999, Journal of medical virology,
Natsumi Omura, and Hikaru Fujii, and Tomoki Yoshikawa, and Souichi Yamada, and Shizuko Harada, and Takuya Inagaki, and Miho Shibamura, and Haruko Takeyama, and Masayuki Saijo
December 1982, The Journal of general virology,
Natsumi Omura, and Hikaru Fujii, and Tomoki Yoshikawa, and Souichi Yamada, and Shizuko Harada, and Takuya Inagaki, and Miho Shibamura, and Haruko Takeyama, and Masayuki Saijo
July 2000, The Journal of infectious diseases,
Natsumi Omura, and Hikaru Fujii, and Tomoki Yoshikawa, and Souichi Yamada, and Shizuko Harada, and Takuya Inagaki, and Miho Shibamura, and Haruko Takeyama, and Masayuki Saijo
November 2006, Antimicrobial agents and chemotherapy,
Natsumi Omura, and Hikaru Fujii, and Tomoki Yoshikawa, and Souichi Yamada, and Shizuko Harada, and Takuya Inagaki, and Miho Shibamura, and Haruko Takeyama, and Masayuki Saijo
September 1982, The New England journal of medicine,
Copied contents to your clipboard!